Literature DB >> 9445267

Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study.

E K Hoogeveen1, P J Kostense, P J Beks, A J Mackaay, C Jakobs, L M Bouter, R J Heine, C D Stehouwer.   

Abstract

A high serum total homocysteine (tHcy) level is an independent risk factor for cardiovascular disease. Because it is not known whether the strength of the association between hyperhomocysteinemia and cardiovascular disease is similar for peripheral arterial, coronary artery, and cerebrovascular disease, we compared the three separate risk estimates in an age-, sex-, and glucose tolerance-stratified random sample (n=631) from a 50- to 75-year-old general white population. Furthermore, we investigated the combined effect of hyperhomocysteinemia and diabetes mellitus with regard to cardiovascular disease. The prevalence of fasting hyperhomocysteinemia (>14.0 micromol/L) was 25.8%. After adjustment for age, sex, hypertension, hypercholesterolemia, diabetes, and smoking, the odds ratios (ORs; 95% confidence intervals) per 5-micromol/L increment in tHcy were 1.44 (1.10 to 1.87) for peripheral arterial, 1.25 (1.03 to 1.51) for coronary artery, 1.24 (0.97 to 1.58) for cerebrovascular, and 1.39 (1.15 to 1.68) for any cardiovascular disease. After stratification by glucose tolerance category and adjustment for the classic risk factors and serum creatinine, the ORs per 5-micromol/L increment in tHcy for any cardiovascular disease were 1.38 (1.03 to 1.85) in normal glucose tolerance, 1.55 (1.01 to 2.38) in impaired glucose tolerance, and 2.33 (1.11 to 4.90) in non-insulin-dependent diabetes mellitus (P=.07 for interaction). We conclude that the magnitude of the association between hyperhomocysteinemia and cardiovascular disease is similar for peripheral arterial, coronary artery, and cerebrovascular disease in a 50- to 75-year-old general population. High serum tHcy may be a stronger (1.6-fold) risk factor for cardiovascular disease in subjects with non-insulin-dependent diabetes mellitus than in nondiabetic subjects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445267     DOI: 10.1161/01.atv.18.1.133

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  55 in total

1.  Homocysteine and cardiovascular disease.

Authors:  A F Winder
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

2.  Methylenetetrahydrofolate reductase gene polymorphism, homocysteine and risk of macroangiopathy in Type 2 diabetes mellitus.

Authors:  J Sun; Y Xu; Y Zhu; H Lu
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

3.  Metformin-induced B12 deficiency: still relevant today.

Authors:  Mohsin Muhktar; Dearbhla Sherry; Laura Keaver; Catherine M McHugh
Journal:  Ir J Med Sci       Date:  2019-07-30       Impact factor: 1.568

Review 4.  The genetics of vascular complications in diabetes mellitus.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

5.  Mild hyperhomocysteinemia and the common C677T polymorphism of methylene tetrahydrofolate reductase gene are not associated with the metabolic syndrome in Type 2 diabetes.

Authors:  G T Russo; A Di Benedetto; E Alessi; R Ientile; A Antico; G Nicocia; R La Scala; E Di Cesare; G Raimondo; D Cucinotta
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

Review 6.  Homocysteine and blood pressure.

Authors:  Coen van Guldener; Prabath W B Nanayakkara; Coen D A Stehouwer
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

7.  Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population.

Authors:  Wei Gao; Yu-Sheng Wang; Peng Zhang; Hai-Yan Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

8.  Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics.

Authors:  Mabrouka El Oudi; Zied Aouni; Haroun Ouertani; Chakib Mazigh; Salem Machghoul
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

9.  Plasma total homocysteine and macrovascular complications are associated with food and nutrient intake in patients with Type II diabetes mellitus.

Authors:  Namsoo Chang; Ji-Myung Kim; Hyesook Kim; Yong Wook Cho
Journal:  Nutr Res Pract       Date:  2007-06-30       Impact factor: 1.926

10.  Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

Authors:  Paras K Mishra; Neetu Tyagi; Utpal Sen; Irving G Joshua; Suresh C Tyagi
Journal:  Cardiovasc Diabetol       Date:  2010-09-09       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.